Project: Treatment enabled by REcombinant Advanced immunotherapy Technologies for HER2 positive tumours
| Acronym | TREAT-HER2 (Reference Number: 113775) |
| Duration | 01/04/2020 - 01/04/2023 |
| Project Topic | We will develop a safe, effective and inexpensive vaccine for treatment of HER2+ cancers and prevention of recurrence. The vaccine combines state-to-the-art technologies in biotechnology and immunomodulation. Objectives are: 1) develop cGMP compatible vaccine manufacturing process; 2) delivery of safety, immunogenicity and efficacy data in (transgenic) mice, rabbits, nonhuman primates, and dogs developing spontaneously HER2+ carcinomas; 3) prepare for an IND/IMPD for a FIH study and partnering. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 12 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | LiteVax | Partner | Netherlands |
| 2 | AdaptVac | Coordinator | Denmark |
| 3 | Biomedical Primate Research Centre | Partner | Netherlands |
| 4 | ExpreS2ion | Partner | Denmark |
| 5 | University of Copenhagen | Partner | Denmark |